Publication

Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer

Journal Paper/Review - Nov 17, 2021

Schneeweiss Andreas, Blohmer Jens-Uwe, Fasching Peter A, Solbach Christine, Schmutzler Rita K, Huober Jens, Rhiem Kerstin, Nekljudova Valentina, Lübbe Kristina, Loibl Sibylle, Jackisch Christian, Untch Michael, Link Theresa, Michel Laura L, Möbus Volker, Tesch Hans, Klare Peter, Hahnen Eric, Denkert Carsten, Kast Karin, Pohl-Rescigno Esther, Hanusch Claus, GBG and AGO-B